1. Home
  2. SEED vs BOLT Comparison

SEED vs BOLT Comparison

Compare SEED & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Agritech Limited

SEED

Origin Agritech Limited

SELL

Current Price

$0.66

Market Cap

8.5M

ML Signal

SELL

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$4.98

Market Cap

7.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEED
BOLT
Founded
1997
2015
Country
China
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
7.7M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
SEED
BOLT
Price
$0.66
$4.98
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $41.00
AVG Volume (30 Days)
10.9K
★ 705.5K
Earning Date
05-21-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,695,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 0.07
52 Week Low
$0.64
$5.06
52 Week High
$1.73
$14.40

Technical Indicators

Market Signals
Indicator
SEED
BOLT
Relative Strength Index (RSI) 37.96 28.59
Support Level N/A N/A
Resistance Level $1.07 $8.72
Average True Range (ATR) 0.04 0.39
MACD -0.00 -0.12
Stochastic Oscillator 3.54 4.28

Price Performance

Historical Comparison
SEED
BOLT

About SEED Origin Agritech Limited

Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: